background image

Paid Clinical Trials Reno

Discover 145 paid clinical trials in Reno, Nevada. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2
Active & Responsive

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

for
PIK3CA Mutation, Solid Tumor, Adult,
Location: 19 recruiting locations
Sponsor: Relay Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05216432

Phase1, Recruiting
Active & Responsive

Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain

for
Degenerative Disc Disease
Location: 39 recruiting locations
Sponsor: Mesoblast, Ltd.

Sex: All

Age: 18+

Code: NCT06325566

Phase3, Recruiting
Active & Responsive

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

for
Lung Cancer Diagnosis
Location: 36 recruiting locations
Sponsor: Freenome Holdings Inc.

Sex: All

Age: 50+

Code: NCT06122077

Recruiting
Active & Responsive

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

for
Platinum-resistant Ovarian Cancer,
Location: 29 recruiting locations
Sponsor: Genelux Corporation

Sex: Female

Age: 18+

Code: NCT05281471

Phase3, Recruiting
Active & Responsive

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

for
Psoriasis, Overweight or Obesity
Location: 42 recruiting locations
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT06857942

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

for
Primary IgA Nephropathy
Location: 36 recruiting locations
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT05797610

Phase3, Recruiting
Active & Responsive

Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus

for
Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema,
Location: 14 recruiting locations
Sponsor: Attovia Therapeutics Inc

Sex: All

Age: 18 - 70+

Code: NCT06787586

Phase1, Recruiting
Active & Responsive

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

for
Idiopathic Pulmonary Fibrosis (IPF)
Location: 24 recruiting locations
Sponsor: Vicore Pharma AB

Sex: All

Age: 40+

Code: NCT06588686

Phase2, Recruiting
Active & Responsive

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

for
PIK3CA Mutation, HER2- Negative Breast Cancer,
Location: 31 recruiting locations
Sponsor: Relay Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06982521

Phase3, Recruiting
Active & Responsive

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

for
Triple Negative Breast Neoplasms
Location: 39 recruiting locations
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06841354

Phase3, Recruiting